CLINICAL INNOVATION ApS: Financial statements 2015
CVR: 29924880
Source: annual report 2015, Danish Business Authority
01/10/2014 – 30/09/2015
CLINICAL INNOVATION ApS (CVR 29924880) has filed annual accounts for 2015. In 2015, the company reported a gross profit of DKK 3,202,811 and a net result of DKK 272,183 compared with DKK 483,057 the year before. That is an increase of 13.5% compared with the year before. Equity in the 2015 report amounted to DKK 3,084,066. The solvency ratio was 38.8%.
- Gross Profit
- DKK 3,202,811
- Profit/Loss
- DKK 272,183
- Equity
- DKK 3,084,066
- Total Assets
- DKK 7,956,885
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2015 | - | 3.2 mio. | 272 t. | 3.1 mio. | - |
| 2014 | - | 2.8 mio. | 483 t. | 2.9 mio. | - |
| 2013 | - | 3 mio. | 545 t. | 2.6 mio. | - |
| 2012 | - | 2.4 mio. | 550 t. | 2.4 mio. | - |
Official annual report
How creditworthy is CLINICAL INNOVATION ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
As of September 30, 2015, Henning Langberg has left the board of directors of CLINICAL INNOVATION ApS.
As of September 30, 2015, Annelise Høy Madsen has left the board of directors of CLINICAL INNOVATION ApS.
CLINICAL INNOVATION ApS has published its annual report for 2014. Gross profit came to DKK 2,821,058, and the net result was DKK 483,057.
About CLINICAL INNOVATION ApS
CLINICAL INNOVATION ApS is a Danish company of the type Anpartsselskab based in Holbæk, founded in 2006. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Claus Michael Dinesen. The board consists of Ole Hedemann (chair), Claus Michael Dinesen, Magnus Oliver Lorentzen Dinesen and Marc Phillip Gall Schultz Lorentzen. The company is owned by PIA & CLAUS DINESEN HOLDING ApS. The company has 5 employees (2026). In 2025, the company reported a gross profit of DKK 2,775,826 and a net result of DKK 413,835 compared with DKK 95,746 the year before. Equity in the 2025 report amounted to DKK 3,821,950.